Inventor
HONJO TASUKU
JP40 patents
⚠️ This page may combine multiple inventors who share the name “HONJO TASUKU”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ONO PHARMACEUTICAL CO
24 patentsUS9439962B2Sep 13, 2016
Immunopotentiative composition
ONO PHARMACEUTICAL CO67 citations99
US9402899B2Aug 2, 2016
Immunopotentiative composition
ONO PHARMACEUTICAL CO93 citations99
US9393301B2Jul 19, 2016
Immunopotentiative composition
ONO PHARMACEUTICAL CO76 citations99
US9073994B2Jul 7, 2015
Immunopotentiative composition
ONO PHARMACEUTICAL CO217 citations99
US9067999B1Jun 30, 2015
Immunopotentiative composition
ONO PHARMACEUTICAL CO173 citations99
US7595048B2Sep 29, 2009
Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
ONO PHARMACEUTICAL CO473 citations99
US7858746B2Dec 28, 2010
Substance that specifically recognizes PD-1
ONO PHARMACEUTICAL CO60 citations98
US7563869B2Jul 21, 2009
Substance specific to human PD-1
ONO PHARMACEUTICAL CO204 citations98
US7998479B2Aug 16, 2011
Substance specific to human PD-1
ONO PHARMACEUTICAL CO57 citations97
US5698520ADec 16, 1997
Peptide related to human programmed cell death and DNA encoding the same
ONO PHARMACEUTICAL CO184 citations97
US5629204AMay 13, 1997
Peptide related to human programmed cell death and DNA encoding it
ONO PHARMACEUTICAL CO127 citations97
US5756084AMay 26, 1998
Human stromal derived factor 1α and 1β
ONO PHARMACEUTICAL CO60 citations94
US5563048AOct 8, 1996
Human stromal derived factor 1α and 1β, and DNAs encoding the same
ONO PHARMACEUTICAL CO66 citations94
US7414171B2Aug 19, 2008
PD-1-lacking mouse and use thereof
ONO PHARMACEUTICAL CO44 citations93
US9783609B2Oct 10, 2017
Substance specific to human PD-1
ONO PHARMACEUTICAL CO8 citations84
US7407767B2Aug 5, 2008
Method of screening remedy for heart disease and medicinal composition for treating heart disease
ONO PHARMACEUTICAL CO10 citations79
US6900031B2May 31, 2005
Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
ONO PHARMACEUTICAL CO4 citations72
US6846647B1Jan 25, 2005
Polypeptides suppressing smooth muscle cell proliferation, the encoding cDNA, and related methods
ONO PHARMACEUTICAL CO5 citations63
US7998491B2Aug 16, 2011
Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
ONO PHARMACEUTICAL CO2 citations61
US7794975B2Sep 14, 2010
Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
ONO PHARMACEUTICAL CO2 citations61
US7217786B2May 15, 2007
Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
ONO PHARMACEUTICAL CO3 citations61
US7749758B2Jul 6, 2010
Human and mammalian stem cell-derived neuron survival factors
ONO PHARMACEUTICAL CO0 citations52
US7662620B2Feb 16, 2010
Human and mammalian stem cell-derived neuron survival factors
ONO PHARMACEUTICAL CO0 citations52
US7273725B2Sep 25, 2007
Human and mammalian stem cell-derived neuron survival factors
ONO PHARMACEUTICAL CO0 citations52
HONJO TASUKU
5 patentsUS8728474B2May 20, 2014
Immunopotentiative composition
HONJO TASUKU305 citations98
US8168179B2May 1, 2012
Treatment method using anti-PD-L1 antibody
HONJO TASUKU349 citations98
US8246955B2Aug 21, 2012
Substance specific to human PD-1
HONJO TASUKU54 citations97
US8951518B2Feb 10, 2015
Substance specific to human PD-1
HONJO TASUKU16 citations92
US5416201AMay 16, 1995
DNAs that code for mouse interleuken 4
HONJO TASUKU1 citations48